Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction

Michelle L. Hastings, Timothy A. Jones

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Antisense oligonucleotides (ASOs) have shown potential as therapeutic molecules for the treatment of inner ear dysfunction. The peripheral sensory organs responsible for both hearing and equilibrium are housed within the inner ear. Hearing loss and vestibular balance problems affect a large portion of the population and limited treatment options exist. Targeting ASOs to the inner ear as a therapeutic strategy has unique pharmacokinetic and drug delivery opportunities and challenges. Here, we review ASO technology, delivery, disease targets, and other key considerations for development of this therapeutic approach.

Original languageEnglish (US)
Pages (from-to)348-359
Number of pages12
JournalNeurotherapeutics
Volume16
Issue number2
DOIs
StatePublished - Apr 15 2019

Fingerprint

Antisense Oligonucleotides
Inner Ear
Therapeutics
Hearing Loss
Hearing
Pharmacokinetics
Technology
Pharmaceutical Preparations
Population

Keywords

  • RNA interference
  • Usher syndrome
  • antisense oligonucleotides
  • deafness
  • hearing loss
  • sensorineural hearing loss
  • splicing

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction. / Hastings, Michelle L.; Jones, Timothy A.

In: Neurotherapeutics, Vol. 16, No. 2, 15.04.2019, p. 348-359.

Research output: Contribution to journalReview article

@article{006e4f306a434c9a9851d8b356ca6714,
title = "Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction",
abstract = "Antisense oligonucleotides (ASOs) have shown potential as therapeutic molecules for the treatment of inner ear dysfunction. The peripheral sensory organs responsible for both hearing and equilibrium are housed within the inner ear. Hearing loss and vestibular balance problems affect a large portion of the population and limited treatment options exist. Targeting ASOs to the inner ear as a therapeutic strategy has unique pharmacokinetic and drug delivery opportunities and challenges. Here, we review ASO technology, delivery, disease targets, and other key considerations for development of this therapeutic approach.",
keywords = "RNA interference, Usher syndrome, antisense oligonucleotides, deafness, hearing loss, sensorineural hearing loss, splicing",
author = "Hastings, {Michelle L.} and Jones, {Timothy A.}",
year = "2019",
month = "4",
day = "15",
doi = "10.1007/s13311-019-00729-0",
language = "English (US)",
volume = "16",
pages = "348--359",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction

AU - Hastings, Michelle L.

AU - Jones, Timothy A.

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Antisense oligonucleotides (ASOs) have shown potential as therapeutic molecules for the treatment of inner ear dysfunction. The peripheral sensory organs responsible for both hearing and equilibrium are housed within the inner ear. Hearing loss and vestibular balance problems affect a large portion of the population and limited treatment options exist. Targeting ASOs to the inner ear as a therapeutic strategy has unique pharmacokinetic and drug delivery opportunities and challenges. Here, we review ASO technology, delivery, disease targets, and other key considerations for development of this therapeutic approach.

AB - Antisense oligonucleotides (ASOs) have shown potential as therapeutic molecules for the treatment of inner ear dysfunction. The peripheral sensory organs responsible for both hearing and equilibrium are housed within the inner ear. Hearing loss and vestibular balance problems affect a large portion of the population and limited treatment options exist. Targeting ASOs to the inner ear as a therapeutic strategy has unique pharmacokinetic and drug delivery opportunities and challenges. Here, we review ASO technology, delivery, disease targets, and other key considerations for development of this therapeutic approach.

KW - RNA interference

KW - Usher syndrome

KW - antisense oligonucleotides

KW - deafness

KW - hearing loss

KW - sensorineural hearing loss

KW - splicing

UR - http://www.scopus.com/inward/record.url?scp=85065206653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065206653&partnerID=8YFLogxK

U2 - 10.1007/s13311-019-00729-0

DO - 10.1007/s13311-019-00729-0

M3 - Review article

C2 - 30972560

AN - SCOPUS:85065206653

VL - 16

SP - 348

EP - 359

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 2

ER -